Pricing Log in Create free account

Beam Therapeutics Inc. (BEAM) vs Telix Pharmaceuticals Limited (TLX)

Beam Therapeutics Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Telix Pharmaceuticals Limited is the larger, with a market value of $3.2B against $2.7B — 1.2× the size. Across the 9 metrics below, Telix Pharmaceuticals Limited leads on 5 and Beam Therapeutics Inc. on 4.

Valuation

Metric BEAM TLX Biotechnology median
P/E n/m — 10.26
P/S 18.63 — 9.18
P/B 2.87 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 12.20 n/m 8.98
Earnings yield (3.85%) — (34.89%)
Free cash flow yield (14.57%) 0.00% (24.52%)

Profitability

Metric BEAM TLX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (267.68%) — 0.00%
Net margin (73.89%) — 0.00%
Free cash flow margin (271.57%) 0.00% 0.00%
Return on equity (11.29%) 0.00% (50.12%)
Return on assets (8.40%) 0.00% (45.60%)
Return on invested capital (2,676.86%) 0.00% 0.00%

Growth

Metric BEAM TLX Biotechnology median
Revenue growth (TTM) 163.27% — 6.26%
EPS growth (last fiscal year) 82.31% (120.00%) 29.88%
Revenue growth, 5-year CAGR 466.27% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BEAM TLX Biotechnology median
Debt to equity 0.11 1.18 0.00
Current ratio 13.00 2.01 4.89
Net debt to EBITDA 3.30 6.25 1.01

Dividend

Metric BEAM TLX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BEAM TLX Biotechnology median
Market cap 2.68b 3.21b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack